What's in Advenchen Laboratories Nanjing Ltd.'s pipeline?

Advenchen Laboratories Nanjing Ltd. has 5 drugs in our index: 1 marketed, 0 filed, 2 in Phase 3, 1 in Phase 2, 1 in Phase 1.

Which companies overlap with Advenchen Laboratories Nanjing Ltd.'s portfolio?

Top competitors by shared drug class: BeBetter Med Inc, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Exelixis, GWT-TUD GmbH, H. Lee Moffitt Cancer Center and Research Institute.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/advenchen-laboratories-nanjing-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Advenchen Laboratories Nanjing Ltd. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Advenchen Laboratories Nanjing Ltd. pipeline: 1 marketed, 0 filed, 2 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 2 Phase 3 1 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Itraconazole capsule	Itraconazole capsule	marketed
AL3818 Capsule	AL3818 Capsule	phase 3	Multi-targeted tyrosine kinase inhibitor	FGFR, VEGFR, and other receptor tyrosine kinases	Oncology
AL8326 tablets	AL8326 tablets	phase 3	Histone deacetylase (HDAC) inhibitor	Histone deacetylase (HDAC)	Oncology

Therapeutic area mix

Oncology · 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

BeBetter Med Inc · 1 shared drug class
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 shared drug class
Exelixis · 1 shared drug class
GWT-TUD GmbH · 1 shared drug class
H. Lee Moffitt Cancer Center and Research Institute · 1 shared drug class
Hanmi Pharmaceutical Company Limited · 1 shared drug class
Mario Negri Institute for Pharmacological Research · 1 shared drug class
Acrotech Biopharma Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Advenchen Laboratories Nanjing Ltd.:

Cite this brief

Drug Landscape (2026). Advenchen Laboratories Nanjing Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/advenchen-laboratories-nanjing-ltd. Accessed 2026-05-17.